论文部分内容阅读
目的比较瑞舒伐他汀与阿托伐他汀治疗冠心病的临床疗效。方法选取来宾市兴宾区疾病预防控制中心2014年11月—2015年11月收治的冠心病患者98例,按照随机法将患者分为对照组49例与观察组49例。两组患者入院后均给予合理膳食干预及常规治疗,对照组给予阿托伐他汀治疗,观察组给予瑞舒伐他汀治疗,于治疗6个月后比较两组患者临床疗效、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)、左心室射血分数(LVEF)、超敏C反应蛋白(hs-CRP)及不良反应发生情况。结果两组患者临床疗效比较,差异无统计学意义(P>0.05)。治疗前两组患者HDL-C、LDL-C、TG、TC水平比较,差异无统计学意义(P>0.05);治疗后观察组患者HDL-C水平高于对照组,LDL-C、TG、TC水平低于对照组(P<0.05)。治疗前两组患者LVEF与hs-CRP比较,差异无统计学意义(P>0.05);治疗后观察组患者LVEF高于对照组,hs-CRP水平低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀与阿托伐他汀治疗冠心病临床疗效相当,均安全有效,但瑞舒伐他汀在改善血脂方面优于阿托伐他汀。
Objective To compare the clinical efficacy of rosuvastatin and atorvastatin in the treatment of coronary heart disease. Methods 98 patients with coronary heart disease were selected from Xingbin CDC from November 2014 to November 2015. The patients were divided into control group (49 cases) and observation group (49 cases) according to the randomized method. Both groups were given reasonable dietary intervention and routine treatment after admission. The control group was treated with atorvastatin, and the observation group was given rosuvastatin. The clinical efficacy, high-density lipoprotein cholesterol HDL-C, LDL-C, TG, TC, LVEF, hs-CRP and Adverse reactions occurred. Results There was no significant difference in clinical efficacy between the two groups (P> 0.05). The levels of HDL-C, LDL-C, TG and TC in the two groups before treatment were no significant difference (P> 0.05). After treatment, the levels of HDL-C in the observation group were higher than those in the control group TC levels were lower than the control group (P <0.05). There was no significant difference in LVEF and hs-CRP between the two groups before treatment (P> 0.05). After treatment, LVEF in observation group was higher than that in control group, hs-CRP level was lower than that in control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusions Rosuvastatin and atorvastatin have similar clinical efficacy and are safe and effective in treating coronary heart disease. Rosuvastatin is superior to atorvastatin in improving blood lipid.